Krystal Biotech (NASDAQ:KRYS) Stock Price Expected to Rise, Citigroup Analyst Says

Krystal Biotech (NASDAQ:KRYS) had its price target lifted by Citigroup from $206.00 to $215.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s price target indicates a potential upside of 14.45% from the company’s previous close.

Other research analysts have also issued reports about the company. Chardan Capital increased their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Up 2.9 %

Shares of KRYS opened at $187.86 on Thursday. The stock’s 50-day moving average price is $157.37 and its 200 day moving average price is $175.23. Krystal Biotech has a 12-month low of $107.50 and a 12-month high of $219.34. The firm has a market capitalization of $5.40 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the company posted $0.30 earnings per share. Krystal Biotech’s revenue was up 116.4% on a year-over-year basis. Equities research analysts expect that Krystal Biotech will post 6.14 EPS for the current year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently made changes to their positions in KRYS. Creative Planning raised its holdings in Krystal Biotech by 64.9% during the 3rd quarter. Creative Planning now owns 5,744 shares of the company’s stock worth $1,046,000 after purchasing an additional 2,260 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after buying an additional 412 shares during the last quarter. Values First Advisors Inc. acquired a new position in Krystal Biotech in the third quarter valued at approximately $53,000. Mount Yale Investment Advisors LLC bought a new position in Krystal Biotech in the third quarter valued at approximately $187,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Krystal Biotech by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,039 shares of the company’s stock worth $184,000 after acquiring an additional 186 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).